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Abstract
This study aimed to evaluate the routine setting performance of a guideline for phenotypic detection of extended spectrum b-lactamases
(ESBLs) in Enterobacteriaceae, recommending ESBL conﬁrmation with Etest or combination disc for isolates with a positive ESBL screen
test (i.e. cefotaxime and/or ceftazidime MIC >1 mg/L or an automated system ESBL warning). Twenty laboratories submitted 443 Entero-
bacteriaceae with a positive ESBL screen test and their conﬁrmation test result (74% Escherichia coli, 12% Enterobacter cloacae, 8% Klebsiella
pneumoniae, 3% Proteus mirabilis, 2% Klebsiella oxytoca). Presence of ESBL genes was used as reference test. Accuracy of local phenotypic
ESBL detection was 88%. The positive predictive value (PPV) of local screen tests was 70%, and differed per method (Vitek-2: 69%, Phoe-
nix: 68%, disc diffusion: 92%), and species (95% K. pneumoniae-27% K. oxytoca). A low PPV (3%) was observed for isolates with automated
system alarm but third-generation cephalosporin MICs <2 mg/L. Local ESBL conﬁrmation had a PPV and negative predictive value (NPV)
of 93% and 90%, respectively. Compared with centrally performed conﬁrmation tests, 7% of local tests were misinterpreted. Combination
disc was more speciﬁc than Etest (91% versus 61%). Conﬁrmation tests were not reliable for P. mirabilis and K. oxytoca (PPV 33% and
38%, respectively, although NPVs were 100%). In conclusion, performance of Etests could be enhanced by education of technicians to
improve their interpretation, by genotypic ESBL conﬁrmation of P. mirabilis and K. oxytoca isolates with positive phenotypic ESBL conﬁrma-
tion, and by interpreting isolates with a positive ESBL alarm but an MIC <2 mg/L for cefotaxime and ceftazidime as ESBL-negative.
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Introduction
The prevalence of extended spectrum b-lactamases (ESBLs) in
Enterobacteriaceae is increasing worldwide [1]. Accurate detec-
tion of ESBLs is necessary for adequate antibiotic therapy,
infection control precautions and surveillance purposes. In
2008, the Dutch Society for Medical Microbiology issued a
guideline for phenotypic screening and conﬁrmation of ESBLs in
Enterobacteriaceae to standardize the method and to improve
the accuracy. In contrast to the CLSI guideline for ESBL detec-
tion, the Dutch guideline also provides methods for phenotypic
ESBL conﬁrmation in Enterobacteriaceae with inducible chro-
mosomal AmpC b-lactamases, using an Etest or combination
disc with cefepime and cefepime plus clavulanic acid.
The objectives of this study were to determine the accu-
racy of phenotypic ESBL detection in Dutch clinical laborato-
ries using this guideline and to compare the performances of




The ESBL detection strategy in the Dutch guideline recom-
mends a screening step and a conﬁrmation step (Fig. 1). Iso-
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lates with a ceftazidime MIC >1 mg/L and/or a cefotaxime
MIC >1 mg/L determined by any MIC method fulﬁlling quality
control criteria, or an ESBL alert in Phoenix (BD Diagnostics,
Sparks, MD, USA) or Vitek-2 (BioMe´rieux Marcy l’Etoile,
France) are considered screen positive. In centres using the
disc diffusion method isolates were selected for ESBL conﬁr-
mation in case of zones £ 20 mm with the Oxoid discs for
ceftazidime or cefotaxime.
Conﬁrmation of ESBL production is based on the detec-
tion of synergy between clavulanic acid and third-generation
cephalosporins. The recommended methods are the ESBL
Etest (BioMe´rieux) or combination discs. The synergy
between cephalosporins and clavulanic acid may be masked
in isolates co-expressing an ESBL and AmpC b-lactamase;
therefore, the Enterobacteriaceae are divided into two
groups, with a speciﬁc strategy for ESBL conﬁrmation for
each. Group I comprises species without inducible chromo-
somal AmpC b-lactamases (Escherichia coli, Klebsiella spp., Pro-
teus mirabilis, Salmonella spp. and Shigella spp.). ESBL
production in these species is conﬁrmed by demonstrating
synergy between ceftazidime and/or cefotaxime and clavula-
nic acid. Group II comprises Enterobacteriaceae with inducible
chromosomal AmpC b-lactamases (Enterobacter spp., Serratia
spp., Providencia spp., Citrobacter freundii, Morganella morganii
and Hafnia alvei). ESBL conﬁrmation in this group is based
on synergy between clavulanic acid and cefepime, a fourth-
generation cephalosporin that is hydrolysed by ESBLs, but
generally not by AmpC b-lactamases [2–4]. The results of
the conﬁrmation test are classiﬁed as positive, negative or
out-of-range.
Isolates
From 1 February 2009 until 1 May 2009, 20 Dutch laborato-
ries submitted all E. coli, Klebsiella pneumoniae, Klebsiella oxy-
toca, P. mirabilis and Enterobacter spp. with a positive ESBL
screen test. For each isolate, participating laboratories pro-
vided information on the method and results of screening
(Vitek, Phoenix, disc diffusion), ESBL conﬁrmation results
(combination disc or Etest), and the MICs of third-generation
cephalosporins from automated systems for isolates with an
ESBL alarm but an MIC of ceftazidime and cefotaxime
<2 mg/L as determined in the reference laboratory. The ﬁrst
25 non-repeat isolates of each laboratory (if available) were
selected for further analysis. Isolates were excluded when: (i)
there was evidence that another isolate was submitted than
originally tested by the participating laboratory (deﬁned as an
eight-fold or higher difference in MICs of the indicator-
cephalosporins reported by the participating and tested by
the central laboratory), or (ii) the phenotypic test results of
the participating laboratory were lacking.
ESBL detection
Phenotypic detection in the reference laboratory was per-
formed by ESBL Etest (BioMe´rieux) or combination disc
+
ESBL screening 






With ceftazidime and cefotaxime +/– clavulanic acid 
(ESBL Etest or combination disk) 
Species with inducible/derepressable chromosomal AmpC gene: 
Enterobacter spp, Citrobacter spp, Morganella morganii, 
Providencia spp, Hafnia alvei, Serratia spp.
Escherichia coli, Klebsiella spp, Proteus mirabilis, Salmonella 
spp, Shigella spp.
ESBL confirmation
With cefepime + clavulanic acid 
(ESBL Etest or combination disk)
Negative: no ESBL2 Nd3 Positive: ESBL4 Negative: no ESBL4 Nd3 Positive: ESBL4
Species determination 
FIG. 1. Extended spectrum b-lactamase (ESBL) detection algorithm for Enterobacteriaceae according to the Dutch guideline for phenotypic ESBL
detection. (1) If cefoxitin resistant, perform cefepime conﬁrmation test. (2) Inhibitor resistant ESBL not excluded. (3) Nd = non-determin-
able = out of range (MIC >Etest strip or no inhibition zone). (4)The ESBL conﬁrmation test may generate false-positive results in K1 b-lactamase
hyperproducing Klebsiella oxytoca. Exceptions are K. oxytoca isolates with high-grade resistance to ceftazidime and synergy between ceftazidime
and clavulanic acid, which is indicative of ESBL production.
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(ROSCO, Taastrup, Denmark). The MICs for ceftazidime
and cefotaxime were determined using micro-broth dilution
(Sensititre, TREK Diagnostic Systems, East Grinstead, UK).
The presence of an ESBL gene was determined using
microarray analysis (Check-KPC ESBL, Check-Points B.V.,
Wageningen, the Netherlands), which detects the most pre-
valent CTX-M, TEM and SHV ESBL gene groups [5]. PCR
and sequencing, using the same DNA batch as used for the
microarray, was performed to determine the exact CTX-M,
TEM and SHV genes. Additional PCRs were performed to
detect the presence of rare ESBL families such as PER, GES
and VEB b-lactamase genes, as well as plasmid-borne Amp-
Cs [6].
ESBL conﬁrmation
The reference method for determining the presence of ESBL
genes consisted of a step-wise procedure.
Step 1. If the results of the phenotypic conﬁrmation tests
reported by the participating laboratory, and the ESBL
microarray results were both positive, the isolate was
deﬁned as ESBL-positive. If both were negative the isolate
was deﬁned as ESBL-negative.
Step 2. If the phenotypic result of the participating labora-
tory and the result of the microarray were discrepant, the
phenotypic conﬁrmation tests (Etest or combination disc,
identical to the test performed in the participating labora-
tory) were repeated in the reference laboratory. If the result
of the repeated phenotypic test conﬁrmed the microarray
result, the isolate was considered accordingly: either ESBL-
positive or ESBL-negative.
Step 3. If there was a discrepancy between the array results
and the repeated phenotypic conﬁrmation test the isolates
were tested with PCR and, if indicated, DNA sequencing.
The results of the PCR and sequencing were considered the
gold standard for the presence of an ESBL gene.
Statistics
Frequency data were analysed with the chi-squared test or
Fisher’s exact if appropriate, using SPSS 15.0
Results
Among the 443 isolates included, E. coli were the most
prevalent (n = 326; 74%), followed by Enterobacter cloacae
(n = 54; 12%), K. pneumoniae (n = 37; 8%), P. mirabilis
(n = 15; 3%) and K. oxytoca (n = 11; 2%). Based on micro-
array and/or sequencing 312 (70%) isolates contained ESBL
genes: 79% CTX-M (66% CTXM-1 group and 12% CTX-M-9
group, <1% other CTX-M groups), 6% TEM (5% TEM-3
group, 1% other TEM groups), 7% SHV (6% SHV-4 group,
1% other SHV groups), 6% a combination of these and 1%
PER or GES.
ESBL screening
Vitek-2 was used for ESBL screening for 350 isolates (79%)
in 16 laboratories, Phoenix was used for 68 isolates (15%) in
three laboratories and the disc diffusion method (Oxoid,
Basingstoke, UK) for 25 isolates (6%) in one laboratory. The
overall positive predictive value (PPV) of local ESBL screening
methods was 70% (312/443). The PPV of the Vitek-2 was
69% (243/350; 95% CI 64–74%), of the Phoenix 68% (46/68;
95% CI 56–78%) and of the disc diffusion method 92% (23/
25; 95% CI 74–99%).
The PPV of ESBL screening—as locally performed—varied
per species: 95% (35/37; 95% CI 81–99%) for K. pneumoniae,
76% (248/326; 95% CI 71–80%) for E. coli, 44% (24/54; 95%
CI 32–58%) for E. cloacae, 13% (2/15; 95% CI 2–39%) for
P. mirabilis, and 27% (3/11; 95% CI 9–57%) for K. oxytoca
(p <0.01 for each species compared with K. pneumoniae). Per
species, the false-positive rate did not depend on the scree-
ning method (data not shown).
The PPV of the ESBL screen tests was inﬂuenced by the
MIC of isolates to ceftazidime and cefotaxime. For the 40
isolates with cefotaxime and ceftazidime MIC <2mg/L, as
determined by broth microdilution in the reference labora-
tory, but an ESBL alarm of the automated system (K. pneu-
moniae 3%, E. coli 10%, E. cloacae 2%, P. mirabilis 33%,
K. oxytoca 36%), the PPV was 3% (1/40), and the rate of
false-positive conﬁrmation tests in those isolates was 30%
(12/40). If isolates had an MIC <2 mg/L for ceftazidime and
cefotaxime in the reference laboratory, this was also the
case in the automated system of the participating labora-
tory, except for two of the 40 cases. Only one isolate (an
E. coli with a cefotaxime MIC of 0.25 and ceftazidime MIC
of 1 mg/L) contained an ESBL gene (CTX-M-1 group). For
403 isolates with a cefotaxime and/or ceftazidime MIC
‡2 mg/L, the PPV of ESBL screening was 77% (311/403) and
the rate of false-positive conﬁrmation tests was only 3%
(12/403). The odds ratio was 131.8 (95% CI 17.9–972.7) for
comparison of PPVs and 0.07 (95% CI 0.03–0.17%) for
false-positive rate.
ESBL conﬁrmation
ESBL conﬁrmation was performed with Etest in 282 isolates
(64%; 13 laboratories), with combination disc in 135 isolates
(30%; six laboratories) and with both Etest and combination
disc in 26 isolates (6%; one laboratory). Overall sensitivity
and speciﬁcity of phenotypic ESBL conﬁrmation tests as
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performed by the local laboratories was 95% and 70%,
respectively (PPV 93% and negative predictive value (NPV)
90%) (Table 1, Fig. 2). The PPV of conﬁrmation tests varied
per species and was ‡95% for E. coli, K. pneumoniae and
E. cloacae, but <40% for K. oxytoca and P. mirabilis (Table 2).
Although sensitivity, PPV and NPV of ESBL conﬁrmation
with Etest and combination discs, as performed in local parti-
cipating laboratories, were comparable, speciﬁcity of the Etest
was 59% (95% CI 48–68%) compared with 92% (95% CI 80–
97%) for the combination disc (Table 1). In the one labora-
tory that conﬁrmed 26 isolates with both conﬁrmation tests,
test characteristics were equal (sensitivity 100% (21/21), spe-
ciﬁcity 80% (4/5), NPV 100% (4/4) and PPV 95% (21/22)).
Discrepancy analysis
For 388 (88%) of 443 isolates the results of phenotypic con-
ﬁrmation tests, as performed by local laboratories, and geno-
typic conﬁrmation of presence or absence of ESBL genes
were concordant. For 32 (7%) of the isolates, phenotypic
results of the local laboratory were discrepant from pheno-
typic conﬁrmation tests repeated in the reference laboratory
as well as genotype conﬁrmation (Fig. 2, step 1). In six iso-
TABLE 1. Comparison of extended spectrum b-lactamase (ESBL) conﬁrmation with Etest versus combination disc in the clini-
cal setting
All isolates n = 443a
(ESBL-positive n = 312
ESBL-negative n = 131)
Etest n = 308
(ESBL-positive n = 221
ESBL-negative n = 87)
Combination disc n = 161
(ESBL-positive n = 113
ESBL-negative n = 48)
p-value (Etest vs
combination disc)
Sensitivity 95% (296/312) 96% (212/221) 93% (105/113) NS
Speciﬁcity 70% (92/131) 59% (51/87)b 92% (44/48) p <0.001
PPVc 93% (296/320) 91% (212/233) 96% (105/109) NS
NPVc 90% (92/102) 94% (51/54) 85% (44/52) NS
an = 443 (Etest n = 282, combination disc n = 135, both Etest and combination disc n = 26 isolates).
bThe participating laboratories reported the ESBL Etest as off-range in 15 of 87 (17%) of the ESBL-negative isolates and as false-positive in 21 of 87 (24%) of the ESBL-nega-
tive isolates.
cFor calculation of the PPV and NPV the off-range Etests were not taken into account.
NPV, negative predictive value; NS, not signiﬁcant; PPV, positive predictive value.
FIG. 2. Diagram of inclusion and test results of isolates. *In ﬁve isolates no cefepime/cefepime plus clavulanic acid Etest was performed.
**Plasmid-borne AmpC.
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lates (in four laboratories) presence of ESBL was missed
because of misinterpretations of Etest (n = 1) and combina-
tion discs (n = 5). Eight isolates (in eight laboratories) were
misclassiﬁed as ESBL-positive because of misinterpretations of
seven Etests and one combination disc. Three of these eight
isolates (38%) had MICs for cefotaxime and/or ceftazidime
<2 mg/L. Furthermore, there were 21 isolates (from nine
laboratories) with non-determinable Etest results, of which
16 (76%) were ESBL-negative when the Etest was repeated in
the central laboratory (Fig. 2). Of those 16 isolates, two iso-
lates harboured a plasmid AmpC, and 12 isolates were proba-
bly chromosomal AmpC producers or had decreased
permeability, as the cefoxitin MICs were ‡16 mg/L (nine
E. coli, two E. cloacae and one P. mirabilis). For the last iso-
lates, the guideline recommends ESBL conﬁrmation with cefe-
pime/cefepime plus clavulanic acid (Fig. 1), but this was not
performed in eight isolates (deviation from protocol).
For 23 (5%) of the 443 isolates, the discordance between
ESBL phenotype and genotype was not the result of inappro-
priate protocol execution. Repeated testing according to
protocol by the reference laboratory failed to conﬁrm phe-
notypic ESBL-positivity in seven isolates. In six isolates clavu-
lanic acid synergy was not observed with cefotaxime,
ceftazidime or cefepime: in all six strains because of inter-
ference of AmpC with the synergy tests (three isolates plas-
mid AmpC, three chromosomal AmpC). Besides, in one
isolate presence of ESBL genes was associated with MICs for
cephalosporins <2 mg/L.
Sixteen isolates were phenotypically ESBL-positive accor-
ding to the protocol, but ESBL genes were not detected in
the array. Nine of those isolates had an MIC <2 mg/L for
cefotaxime and ceftazidime, of which three K. oxytoca iso-
lates, which may have been false-positive because of produc-
tion of the chromosomal OXY (or K1) class A b-lactamase,
and six isolates contained an OXA-1 b-lactamase gene. Of
the seven remaining isolates, two were K. oxytoca, four E. coli
isolates had no genetic substrate for the false positivity (one
CIT positive, the other three contained no b-lactamases),
and one E. coli isolate was SHV-1 positive, with a susceptibi-
lity pattern compatible with SHV-1 hyperproduction
(reduced susceptibility to ceftazidime and amoxicillin-clavul-
anic acid, but susceptible to cefotaxime and cefuroxime) [7].
Therefore, we conclude that the guideline will have a
maximum accuracy compared with the used genotyping
methods of 94% (95% CI 92–96%) (Fig. 2, step 2). Substitu-
tion of the misinterpreted local conﬁrmation results with
centrally performed test results yielded sensitivities of the
Etest and combination discs of 97% (95% CI 94–99%) and
97% (95% CI 92–99%), respectively, and speciﬁcities of 82%
(95% CI 72–88%) and 94% (95% CI 82–98%), respectively.
Discussion
Based on the results from 20 clinical microbiology laborato-
ries in the Netherlands we conclude that application of the
Dutch national guideline for phenotypic ESBL detection
resulted in correct interpretation of the ESBL status in 388
(88%) of 443 isolates with a positive ESBL screen test. Of
note, discordance between phenotypic testing and genotypic
conﬁrmation remained even after extensive retesting in the
reference laboratory for 23 of the incorrect interpretations
(5% of all isolates). Based on our ﬁndings we provide speciﬁc
recommendations to further optimize phenotypic ESBL
detection in routine microbiology diagnostics. These include
genotypic ESBL testing for P. mirabilis and K. oxytoca isolates
with a positive ESBL conﬁrmation test, and to interpret
isolates with MIC <2 mg/L for cefotaxime or ceftazidime
(but considered as ESBL-positive in automated testing) as
ESBL-negative.
The PPV of ESBL screening was 70% and depended on the
method, the species, and the third-generation cephalosporin
MICs. ESBL screening accuracy was comparable for the Vi-
tek-2 and Phoenix methods. Disc diffusion appeared more
speciﬁc, but results were based on one laboratory and 6% of
all isolates only. Per species, PPV ranged from 95% for
TABLE 2. Performance of extended spectrum b-lactamase (ESBL) conﬁrmation in Enterobacteriaceae without (group I) and







E. coli n = 326
ESBL + n = 248
(76%)
K. pneumoniae n = 37
ESBL + n = 35
(95%)
P. mirabilis n = 15
ESBL + n = 2
(13%)
K. oxytoca n = 11
ESBL + n = 3
(27%)
Group II (n = 54)
Enterobacter cloacae
ESBL + n = 24 (44%)
Sensitivity 96% (276/288) 96% (238/248) 94% (33/35) 100% (2/2) 100% (3/3) 83% (20/24)
Speciﬁcity 65% (66/101) 69% (54/78) 1/2a 62% (8/13) 38% (3/8) 87% (26/30)
PPV 92% (276/299) 95% (238/251) 97% (33/34) 33% (2/6) 38% (3/8) 95% (20/21)
NPV 90% (66/73) 90% (54/60) 1/2a 100% (8/8) 100% (3/3) 90% (26/29)
aOnly two ESBL-negative K. pneumoniae isolates were included, one of which was incorrectly reported as false-positive in the ESBL conﬁrmation test.
NPV, negative predictive value; NS, not signiﬁcant; PPV, positive predictive value.
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K. pneumoniae to 13% for P. mirabilis. As a consequence, the
diagnostic yield of ESBL conﬁrmation tests is rather limited
for K. pneumoniae, but deﬁnitely indicated for all other spe-
cies. The accuracy of ESBL screening with automated sys-
tems correlated with the MIC for third-generation
cephalosporins, as measured by broth microdilution. An
extremely low PPV of screening (3%) was observed in iso-
lates with an ESBL alarm of the automated system but third-
generation cephalosporin MICs <2 mg/L.
The accuracy of ESBL conﬁrmation tests also depended
on the conﬁrmation method, species, and the third-genera-
tion cephalosporin MICs. The test characteristics of combi-
nation disc and Etest for ESBL conﬁrmation, as performed by
the participating laboratories, were generally comparable, but
ESBL Etests were less speciﬁc than combination discs (59%
vs. 92%). This was because of non-determinable and false-
positive Etest results. Most Etest results (86%) reported as
off-range could not be conﬁrmed in the reference labora-
tory, indicating problems with the interpretation of the ESBL
Etests and/or lack of expertise in the clinical setting. This
problem was not observed in previous experimental studies
using the Etests as ESBL conﬁrmation test [8,9]. These data
indicate that education of the technicians may improve the
accuracy of ESBL conﬁrmation tests with 8% for Etest and
4% for combination disc results. It should be noted that the
combination discs are cheaper than the Etest.
The PPV of the ESBL conﬁrmation test in E. coli, K. pneu-
moniae and Enterobacter spp. was 95–97% versus 33–38% in
P. mirabilis and K. oxytoca. However, a negative conﬁrmation
test result excluded ESBL production (NPV 100%, Table 2).
Especially the low PPV for P. mirabilis is noticeable and, to
our knowledge, not reported before. As four out of ﬁve
false-positive phenotypic test results could not be repro-
duced in the reference laboratory these false-positive results
suggest difﬁculties with the ESBL conﬁrmation test interpre-
tation, possibly because of swarming of the isolates.
For P. mirabilis and K. oxytoca we recommend a genotypic
ESBL detection method if the phenotypic ESBL conﬁrmation
test is positive.
The accuracy of the conﬁrmation test was low in isolates
with an ESBL alarm from the automated system and a third-
generation cephalosporin MIC <2 mg/L. False-positive conﬁr-
mation results were frequently obtained in such isolates.
We, therefore, recommend that such isolates be interpreted
as ESBL-negative and ESBL conﬁrmation tests should not be
performed. According to our ﬁndings, this strategy would
not signiﬁcantly reduce the sensitivity, but decrease the rate
of false-positive test results with 50%.
Genetic analysis showed that six isolates without an ESBL
genotype, but an ESBL-positive conﬁrmation test in the ref-
erence laboratory and an MIC <2 mg/L for cefotaxime and
ceftazidime, contained an OXA-1 gene (combined with a
TEM-1 in two isolates). These six isolates showed decreased
susceptibility to cefepime (median MIC 6 mg/L, range 1–
8 mg/L) and a positive PM/PML conﬁrmation Etest result, in
line with a recent report that expression of OXA-1 may lead
to false-positive ESBL test results because of fourth-genera-
tion cephalosporin resistance without resistance to cefotax-
ime and ceftazidime [10].
In contrast to the CLSI guideline for ESBL detection,
the Dutch guideline also provides an adequate method for
phenotypic ESBL conﬁrmation in Enterobacteriaceae with
inducible chromosomal AmpC b-lactamases, using an Etest
or combination disc with cefepime and cefepime plus cla-
vulanic acid. Previous studies using cefepime-clavulanate
disc combinations for conﬁrmation reported a sensitivity of
88% and a speciﬁcity of 91% in a research setting [2,11].
Our ﬁndings demonstrate that application of the Dutch
guideline is associated with equally high accuracy in daily
clinical practice.
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